167 related articles for article (PubMed ID: 34799696)
1. COVID-19 vaccination and cancer immunotherapy: should they stick together?
Brest P; Mograbi B; Hofman P; Milano G
Br J Cancer; 2022 Jan; 126(1):1-3. PubMed ID: 34799696
[TBL] [Abstract][Full Text] [Related]
2. The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't.
Malek AE; Cornejo PP; Daoud N; Alam M
Immunotherapy; 2022 Feb; 14(2):91-94. PubMed ID: 34747190
[No Abstract] [Full Text] [Related]
3. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
[TBL] [Abstract][Full Text] [Related]
4. Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: A retrospective single-center study.
Kian W; Zemel M; Kestenbaum EH; Rouvinov K; Alguayn W; Levitas D; Ievko A; Michlin R; Abod MA; Massalha I; Chernomordikov E; Sharb AA; Shalata W; Levison E; Roisman LC; Lavrenkov K; Peled N; Nesher L; Yakobson A
Medicine (Baltimore); 2022 Jan; 101(2):e28561. PubMed ID: 35029223
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.
Chen YW; Tucker MD; Beckermann KE; Iams WT; Rini BI; Johnson DB
Eur J Cancer; 2021 Sep; 155():291-293. PubMed ID: 34400057
[No Abstract] [Full Text] [Related]
6. Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations.
Abid MB
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931473
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 Updates: Pfizer-BioNTech COVID-19 vaccine.
Med Lett Drugs Ther; 2022 Jan; 64(1642):16. PubMed ID: 35134045
[No Abstract] [Full Text] [Related]
8. Severe cutaneous adverse reaction following COVID-19 vaccination and immunotherapy: a second hit?
Hussain K; Kawsar A; Weir J; Au L; Turajlic S; Larkin J; Fearfield L
Clin Exp Dermatol; 2022 Jan; 47(1):149-151. PubMed ID: 34260095
[No Abstract] [Full Text] [Related]
9. Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment.
Buttiron Webber T; Provinciali N; Musso M; Ugolini M; Boitano M; Clavarezza M; D'Amico M; Defferrari C; Gozza A; Briata IM; Magnani M; Paciolla F; Menghini N; Marcenaro E; De Palma R; Sacchi N; Innocenti L; Siri G; D'Ecclesiis O; Cevasco I; Gandini S; DeCensi A
Eur J Cancer; 2021 Dec; 159():105-112. PubMed ID: 34742157
[TBL] [Abstract][Full Text] [Related]
10. In brief: Pfizer/BioNTech COVID-19 vaccine authorized for children 5-11 years old.
Med Lett Drugs Ther; 2021 Nov; 63(1638):185. PubMed ID: 35085214
[No Abstract] [Full Text] [Related]
11. Spike Antibody Titers Evaluation after a 2-Dose Regimen of BNT162b2 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2.
Kayukawa S; Nanya K; Morita M; Ina K; Ota Y; Hasegawa S
Microbiol Spectr; 2021 Dec; 9(3):e0103621. PubMed ID: 34756062
[No Abstract] [Full Text] [Related]
12. Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer.
Debie Y; Vandamme T; Goossens ME; van Dam PA; Peeters M
Eur J Cancer; 2022 Mar; 163():177-179. PubMed ID: 35077960
[No Abstract] [Full Text] [Related]
13. Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up.
Lasagna A; Lilleri D; Agustoni F; Percivalle E; Borgetto S; Alessio N; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Secondino S; Falzoni M; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2022 Feb; 7(1):100359. PubMed ID: 34973510
[TBL] [Abstract][Full Text] [Related]
14. Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience.
Gilboa M; Mandelboim M; Indenbaum V; Lustig Y; Cohen C; Rahav G; Asraf K; Amit S; Jaber H; Nemet I; Kliker L; Bar-Haim E; Mendelson E; Doolman R; Rubin C; Regev-Yochay G; Kreiss Y
J Infect Dis; 2022 Mar; 225(5):785-792. PubMed ID: 34850049
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis.
Saadeldin MK; Abdel-Aziz AK; Abdellatif A
Med Hypotheses; 2021 Jan; 146():110365. PubMed ID: 33221134
[TBL] [Abstract][Full Text] [Related]
16. Immune-related adverse events: what we've learned and where we're heading.
Badran YR; Leet DE; Dougan M
Expert Rev Anticancer Ther; 2020 Sep; 20(9):727-730. PubMed ID: 32726153
[No Abstract] [Full Text] [Related]
17. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.
Nemet I; Kliker L; Lustig Y; Zuckerman N; Erster O; Cohen C; Kreiss Y; Alroy-Preis S; Regev-Yochay G; Mendelson E; Mandelboim M
N Engl J Med; 2022 Feb; 386(5):492-494. PubMed ID: 34965337
[No Abstract] [Full Text] [Related]
18. Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report.
Lasagna A; Lenti MV; Cassaniti I; Sacchi P
Immunotherapy; 2022 Aug; 14(12):915-925. PubMed ID: 35694999
[TBL] [Abstract][Full Text] [Related]
19. Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma.
Avivi I; Balaban R; Shragai T; Sheffer G; Morales M; Aharon A; Lowenton-Spier N; Trestman S; Perry C; Benyamini N; Mittelman M; Tabib Y; Bar Lev T; Zavaro M; Herishanu Y; Luttwak E; Cohen YC
Br J Haematol; 2021 Oct; 195(2):186-193. PubMed ID: 34196388
[TBL] [Abstract][Full Text] [Related]
20. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
Shaw RH; Stuart A; Greenland M; Liu X; Nguyen Van-Tam JS; Snape MD;
Lancet; 2021 May; 397(10289):2043-2046. PubMed ID: 33991480
[No Abstract] [Full Text] [Related]
[Next] [New Search]
